



**ASX & MEDIA RELEASE**

**17 JANUARY 2019**

**MEDLAB RECEIVES FORMAL SME QUALIFICATION FROM EUROPEAN MEDICINES AGENCY**

- Medlab receives formal SME qualification from European Medicines Agency (EMA)

Australian medical life sciences company, Medlab Clinical Ltd (ASX: MDC) is pleased to announce that through its recently incorporated wholly owned subsidiary MDC Europe Limited, it has received formal SME qualification from EMA. MDC Europe Limited is listed on the Register at [https://fmapps.emea.europa.eu/SME/search\\_results2.php?CompanyName=MDC&CompanyActivity=&Country=&search\\_submit=Searchspecifically](https://fmapps.emea.europa.eu/SME/search_results2.php?CompanyName=MDC&CompanyActivity=&Country=&search_submit=Searchspecifically).

EMA is the European equivalent to the Australian TGA and the US FDA.

As part of the registration, this allows MDC to apply for scientific advice, drug evaluation and registration of NanaBis™ (Medlab's patented cannabis-based medicine). It also provides MDC the opportunity to obtain fee reductions up to 90% in the process.

Medlab CEO, Dr Sean Hall said, "this is a significant milestone for MDC. Drug registration of NanaBis™ is key part of the Company's plans and this qualification allows us to start the process into Europe. Drug evaluation and registration fees with the various agencies are expensive, but at the same time, a much needed and real cost in bringing a drug to market and we welcome the opportunity obtain fee reductions and as a result significant savings."

Dr Hall further added, "personally I would like to thank EMA for their collaborative approach in this regard, and very much look forward to escalating the NanaBis™ evaluation with EMA as we move closer to an approved drug in the EU."

**BACKGROUND**

NanaBis™ is MDC's Patent Pending, NanoCelled CBD/THC buccal spray currently in the second stage of advanced cancer pain trials in AU. NanaBis™ is a non-ARTG item and available for use via the Australian Government's Special Access Program. NanaBis™ is currently before several Regulatory Agencies for potentiated FastTrack drug approval pathways.

---

<b>ISSUED FOR:</b>	<b>MEDLAB CLINICAL LTD (ASX: MDC) – <a href="http://www.medlab.co">www.medlab.co</a></b>
<b>FOR FURTHER INFORMATION:</b>	<b>DR SEAN HALL, CEO, MEDLAB CLINICAL TEL: +61 2 8203 9520, <a href="mailto:sean_hall@medlab.co">sean_hall@medlab.co</a></b>
<b>ISSUED BY:</b>	<b>HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL TEL +61 2 9286 1226 OR +61 468 960 457, <a href="mailto:marcha.vandenheuvel@hkstrategies.com">marcha.vandenheuvel@hkstrategies.com</a></b>

**ABOUT MEDLAB – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.

Medlab Clinical Limited, 66 McCauley St, Alexandria NSW 2015  
P: +61 2 8188 0311 F: +61 2 9699 3347 W: [www.medlab.co](http://www.medlab.co)